All News

Officials from the FDA have approved the Janssen Pharmaceutical Companies of Johnson & Johnson’s canagliflozin (Invokana) to reduce the risk of end-stage kidney disease (ESKD) and cardiovascular events in patients with Type 2 Diabetes and chronic kidney disease (CKD).

The report highlighted the reasoning for the drug shortage as well as specific applicants and manufacturers that the agency will be working with to mitigate the supply of Ig products.

Along with her B.S. in pharmacy from UNC-Chapel Hill, author Amy Greeson’s education has included some much more unique experiences. She’s been to Belize to study native therapies, studied in the Amazon with a local medicine man and woman, and learned from traditional healers in Mexico.

The FDA has given the green light to rituximab (Rituxan) injection for the treatment of granulomatosis with polyangiitus (GPA) and microscopic polyangiitis (MPA) in children age 2 and older in combination with glucocorticoids. The application was approved under priority review and with orphan designation.